SLIT2 and chronic myelogenous leukemia, BCR-ABL1 positive: To determine the correlation between SLIT2 promoter methylation and clinicopathological characteristics of CML, the whole cohort of CML patients was divided into two groups based on the previously set cut-off points [12].